BioLineRx annual free cash flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
BioLineRx Free Cash Flow (FCF) History (BLRX)
BioLineRx reported −$8.1M in free cash flow for fiscal 2025, an increase of $35.8M from the previous fiscal year, with a free cash flow margin of −686.36%.
View full BioLineRx company overviewBioLineRx free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$8.1M | $35.8M | — | −686.36% |
| 2024 | 2024-12-31 | −$43.9M | −$21.2M | — | −151.78% |
| 2023 | 2023-12-31 | −$22.7M | $3.6M | — | −473.42% |
| 2022 | 2022-12-31 | −$26.4M | −$2.7M | — | — |
| 2021 | 2021-12-31 | −$23.7M | −$464,000 | — | — |
| 2020 | 2020-12-31 | −$23.2M | −$473,000 | — | — |
| 2019 | 2019-12-31 | −$22.7M | $1.6M | — | — |
| 2018 | 2018-12-31 | −$24.4M | −$3.5M | — | — |
| 2017 | 2017-12-31 | −$20.9M | −$6.3M | — | — |
| 2016 | 2016-12-31 | −$14.6M | $2.3M | — | — |
| 2015 | 2015-12-31 | −$16.9M | — | — | — |
BioLineRx quarterly free cash flow
No reported data
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|
BioLineRx free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$23.2M to −$8.1M, a net increase of $15.1M.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review BioLineRx filings at SEC.gov ↗